More light at the end of the tunnel – apixaban in atrial fibrillation

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.21, Iss.8, 2012-08, pp. : 1235-1239

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New Advances in Atrial Fibrillation Management: The Role of Apixaban

Current Drug Targets, Vol. 19, Iss. 6, 2018-04 ,pp. : 585-592

Bentham Science Publishers

Access to resources Recommend Favorite

Changing anticoagulant paradigms for atrial fibrillation: dabigatran, apixaban and rivaroxaban

By Giorgi Mariano A Cohen Arazi Hernáán Gonzalez Claudio D Di Girolamo Guillermo

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 4, 2011-03 ,pp. : 567-577

Informa Healthcare

Access to resources Recommend Favorite

Light at the end of the tunnel for Barrett's oesophagus

Inpharma, Vol. 1, Iss. 1255, 2000-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Apixaban: Effective and Safe in Preventing Thromboembolic Events in Patients with Atrial Fibrillation and Renal Failure

Current Medicinal Chemistry, Vol. 24, Iss. 34, 2017-11 ,pp. : 3813-3827

Bentham Science Publishers

Access to resources Recommend Favorite

Teduglutide in intestinal adaptation and repair: light at the end of the tunnel

By Mardini Houssam E de Villiers Willem JS

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 6, 2008-06 ,pp. : 945-951

Informa Healthcare

Access to resources Recommend Favorite